The effect of Compound Danshen Dripping Pills on the pharmacokinetics of steady-state warfarin in rats

I couldn't help but chuckle at testing rat poison(warfarin) in rats. That and the dripping pills
http://www.cabdirect.org/abstracts/20123330687.html;jsessionid=C17D191D49D839672677E7FA54504ED7

Abstract

Objective: To determine the potential interaction between the Chinese herb medicine, Compound Danshen Dripping Pills (CDDP) and a widely used oral anticoagulant warfarin in steady-state in vivo when administered concomitantly. Method: Each day for 4 days the warfarin control group and the warfarin plus single-dose of CDDP group of rats were treated orally with warfarin (0.2 mg/kg, once per day at 8 a. m.), and the warfarin and CDDP combined treatment group of rats were treated orally with warfarin (0.2 mg/kg, once per day at 8 a. m.) and CDDP (500 mg/kg, once per day at 8 a. m.), the warfarin steady-state was achieved after 4 days of treatment, blood samples were collected each day (at 8 a. m.) for HPLC analysis. Until the 5 day the warfarin control group of rats were still treated orally with warfarin (0.2 mg/kg, once at 8 a. m.), the warfarin plus single-dose of CDDP group of rats were treated orally with warfarin (0.2 mg/kg, once at 8 a. m.) and CDDP (500 mg/kg, once at 8 a. m.), and the warfarin and CDDP combined treatment group of rats were still treated orally with warfarin (0.2 mg/kg, once at 8 a. m.) and CDDP (500 mg/kg, once at 8 a. m.), and blood samples were collected at 0, 0.5, 1, 2, 4, 8, 12, 24, 36, 48 h after warfarin-treatment. The concentration of warfarin in blood plasma was determined by high performance liquid chromatography (HPLC). Result: The linear calibration curve ranged from 0.05 to 10 µg/ml, the limit of quantitation (LLOQ) for warfarin was 0.05 ng/ml (r>0.999), moreover, all the validation data including accuracy, precision (intra- and inter-day), sensitivity, recovery, stability, were within the required limits. CDDP did not alter the pharmacokinetic (PK) behavior of warfarin in steady-state in vivo in rats after simultaneous and concomitant treatment. Conclusion: The simultaneous and concomitant treatment of rats with CDDP did not give rise to significant effects on the pharmacokinetics in steady-state of warfarin.